Current advances in the study of diabetic cardiomyopathy: From clinicopathological features to molecular therapeutics (Review)
- Authors:
- Lin Sun
- Ming Yu
- Tong Zhou
- Siwen Zhang
- Guangyu He
- Guixia Wang
- Xiaokun Gang
-
Affiliations: Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Cardiology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130021, P.R. China - Published online on: July 4, 2019 https://doi.org/10.3892/mmr.2019.10473
- Pages: 2051-2062
This article is mentioned in:
Abstract
 |
|
Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, et al: Executive summary: Heart disease and stroke statistics-2010 update: A report from the American heart association. Circulation. 121:948–954. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Boyle JP, Thompson TJ, Gregg EW, Barker LE and Williamson DF: Projection of the year 2050 burden of diabetes in the US adult population: Dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 8:292010. View Article : Google Scholar : PubMed/NCBI | |
|
Regensteiner JG, Golden S, Huebschmann AG, Barrett-Connor E, Chang AY, Chyun D, Fox CS, Kim C, Mehta N, Reckelhoff JF, et al: Sex differences in the cardiovascular consequences of diabetes mellitus: A scientific statement from the American heart association. Circulation. 132:2424–2447. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW and Grishman A: New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 30:595–602. 1972. View Article : Google Scholar : PubMed/NCBI | |
|
Authors/Task Force Members, ; Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, et al: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 34:3035–3087. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, et al: 2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol. 62:e147–e239. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Jia G, Whaley-Connell A and Sowers JR: Diabetic cardiomyopathy: A hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia. 61:21–28. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR and Rodeheffer RJ: Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA. 289:194–202. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Miki T, Yuda S, Kouzu H and Miura T: Diabetic cardiomyopathy: Pathophysiology and clinical features. Heart Fail Rev. 18:149–166. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Song Y, Wang Q, Kralik PM and Epstein PN: Causes and characteristics of diabetic cardiomyopathy. Rev Diabet Stud. 3:108–117. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Pappachan JM, Varughese GI, Sriraman R and Arunagirinathan G: Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and management. World J Diabetes. 4:177–189. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ghosh N and Katare R: Molecular mechanism of diabetic cardiomyopathy and modulation of microRNA function by synthetic oligonucleotides. Cardiovasc Diabetol. 17:432018. View Article : Google Scholar : PubMed/NCBI | |
|
Varma U, Koutsifeli P, Benson VL, Mellor KM and Delbridge LMD: Molecular mechanisms of cardiac pathology in diabetes-Experimental insights. Biochim Biophys Acta Mol Basis Dis. 1864:1949–1959. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kang Y, Wang S, Huang J, Cai L and Keller BB: Right ventricular dysfunction and remodeling in diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol. 316:H113–H122. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tarquini R, Pala L, Brancati S, De Cosmo S, Mazzoccoli G and Rotella CM: Clinical approach to diabetic cardiomyopathy: A review of human studies. Curr Med Chem. 25:1510–1524. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gao S, Ho D, Vatner DE and Vatner SF: Echocardiography in mice. Curr Protoc Mouse Biol. 1:71–83. 2011.PubMed/NCBI | |
|
Qian C, Gong L, Yang Z, Chen W, Chen Y, Xu Z, Wu B, Tang C, Gao F and Zeng W: Diastolic dysfunction in spontaneous type 2 diabetes rhesus monkeys: A study using echocardiography and magnetic resonance imaging. BMC Cardiovasc Disord. 15:592015. View Article : Google Scholar : PubMed/NCBI | |
|
Caglar Acar O, Epcacan S, Uner A, Ece I and Dogan M: Evaluation of left and right ventricular functions using conventional and tissue Doppler echocardiography in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 29:885–891. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Danzmann LC, Bodanese LC, Köhler I and Torres MR: Left atrioventricular remodeling in the assessment of the left ventricle diastolic function in patients with heart failure: A review of the currently studied echocardiographic variables. Cardiovasc Ultrasound. 6:562008. View Article : Google Scholar : PubMed/NCBI | |
|
Yu CM, Sanderson JE, Marwick TH and Oh JK: Tissue Doppler imaging a new prognosticator for cardiovascular diseases. J Am Coll Cardiol. 49:1903–1914. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Malm S, Frigstad S, Sagberg E, Larsson H and Skjaerpe T: Accurate and reproducible measurement of left ventricular volume and ejection fraction by contrast echocardiography: A comparison with magnetic resonance imaging. J Am Coll Cardiol. 44:1030–1035. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Cosyns B, Droogmans S, Hernot S, Degaillier C, Garbar C, Weytjens C, Roosens B, Schoors D, Lahoutte T, Franken PR and Van Camp G: Effect of streptozotocin-induced diabetes on myocardial blood flow reserve assessed by myocardial contrast echocardiography in rats. Cardiovasc Diabetol. 7:262008. View Article : Google Scholar : PubMed/NCBI | |
|
Wang D, Xu JZ, Chen X, Xu TY, Zhang W, Li Y and Wang JG: Left atrial myocardial dysfunction in patients with primary aldosteronism as assessed by speckle-tracking echocardiography. J hypertension. May 30–2019.(Epub ahead of print). View Article : Google Scholar | |
|
Cameli M, Mondillo S, Galderisi M, Mandoli GE, Ballo P, Nistri S, Capo V, D'Ascenzi F, D'Andrea A, Esposito R, et al: Speckle tracking echocardiography: A practical guide. G Ital Cardiol (Rome). 18:253–269. 2017.(In Italian). PubMed/NCBI | |
|
Enomoto M, Ishizu T, Seo Y, Kameda Y, Suzuki H, Shimano H, Kawakami Y and Aonuma K: Myocardial dysfunction identified by three-dimensional speckle tracking echocardiography in type 2 diabetes patients relates to complications of microangiopathy. J Cardiol. 68:282–287. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fang ZY, Schull-Meade R, Leano R, Mottram PM, Prins JB and Marwick TH: Screening for heart disease in diabetic subjects. Am Heart J. 149:349–354. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, de Roos A and Lamb HJ: Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 52:1793–1799. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kwong RY and Korlakunta H: Diagnostic and prognostic value of cardiac magnetic resonance imaging in assessing myocardial viability. Top Magn Reson Imaging. 19:15–24. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Sorrell VL and Reeves WC: Noninvasive right and left heart catheterization: Taking the echo lab beyond an image-only laboratory. Echocardiography. 18:31–41. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Grady RM, Eisenberg PR and Bridges ND: Rational approach to use of heparin during cardiac catheterization in children. J Am Coll Cardiol. 25:725–729. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Kindermann M: How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography associations of the European society of cardiology. Eur Heart J. 28:2686–2687. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yang FB, Guo WL, Sheng M, Sun L, Ding YY, Xu QQ, Xu MG and Lv HT: Diagnostic accuracy of coronary angiography using 64-slice computed tomography in coronary artery disease. Saudi Med J. 36:1156–1162. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dharampal AS, Rossi A and de Feyter PJ: Computed tomography-coronary angiography in the detection of coronary artery disease. J Cardiovasc Med (Hagerstown). 12:554–561. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jiangping S, Zhe Z, Wei W, Yunhu S, Jie H, Hongyue W, Hong Z and Shengshou H: Assessment of coronary artery stenosis by coronary angiography: A head-to-head comparison with pathological coronary artery anatomy. Circ Cardiovasc Interv. 6:262–268. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Dinh W, Bansemir L, Füth R, Nickl W, Stasch JP, Coll-Barroso M, Lapp H, Bufe A, Wolfertz J, Scheffold T and Lankisch M: Increased levels of laminin and collagen type VI may reflect early remodelling in patients with acute myocardial infarction. Acta Cardiol. 64:329–334. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
D'Souza A, Howarth FC, Yanni J, Dobryznski H, Boyett MR, Adeghate E, Bidasee KR and Singh J: Left ventricle structural remodelling in the prediabetic Goto-Kakizaki rat. Exp Physiol. 96:875–888. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chen LC, Shibu MA, Liu CJ, Han CK, Ju DT, Chen PY, Viswanadha VP, Lai CH, Kuo WW and Huang CY: ERK1/2 mediates the lipopolysaccharide-induced upregulation of FGF-2, uPA, MMP-2, MMP-9 and cellular migration in cardiac fibroblasts. Chem Biol Interact. 306:62–69. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
DeLeon-Pennell KY, Meschiari CA, Jung M and Lindsey ML: Matrix metalloproteinases in myocardial infarction and heart failure. Prog Mol Biol Transl Sci. 147:75–100. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Radosinska J, Barancik M and Vrbjar N: Heart failure and role of circulating MMP-2 and MMP-9. Panminerva Med. 59:241–253. 2017.PubMed/NCBI | |
|
Tanaka K, Essick EE, Doros G, Tanriverdi K, Connors LH, Seldin DC and Sam F: Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis. J Am Heart Assoc. 2:e0058682013. View Article : Google Scholar : PubMed/NCBI | |
|
Ban CR, Twigg SM, Franjic B, Brooks BA, Celermajer D, Yue DK and McLennan SV: Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic dysfunction. Diabetes Res Clin Pract. 87:335–341. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yeh JK, Chen CC, Hsieh MJ, Tsai ML, Yang CH, Chen DY, Chang SH, Wang CY, Lee CH and Hsieh IC: Impact of homocysteine level on long-term cardiovascular outcomes in patients after coronary artery stenting. J Atheroscler Thromb. 24:696–705. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Shargorodsky M, Boaz M, Pasternak S, Hanah R, Matas Z, Fux A, Beigel Y and Mashavi M: Serum homocysteine, folate, vitamin B12 levels and arterial stiffness in diabetic patients: Which of them is really important in atherogenesis? Diabetes Metab Res Rev. 25:70–75. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mishra PK, Tyagi N, Sen U, Joshua IG and Tyagi SC: Synergism in hyperhomocysteinemia and diabetes: Role of PPAR gamma and tempol. Cardiovasc Diabetol. 9:492010. View Article : Google Scholar : PubMed/NCBI | |
|
Chavali V, Tyagi SC and Mishra PK: Predictors and prevention of diabetic cardiomyopathy. Diabetes Metab Syndr Obes. 6:151–160. 2013.PubMed/NCBI | |
|
Hayden MR and Tyagi SC: Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: The pleiotropic effects of folate supplementation. Nutr J. 3:42004. View Article : Google Scholar : PubMed/NCBI | |
|
Quilliot D, Alla F, Böhme P, Bruntz JF, Hammadi M, Dousset B, Ziegler O and Zannad F: Myocardial collagen turnover in normotensive obese patients: Relation to insulin resistance. Int J Obes (Lond). 29:1321–1328. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Epshteyn V, Morrison K, Krishnaswamy P, Kazanegra R, Clopton P, Mudaliar S, Edelman S, Henry R and Maisel A: Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care. 26:2081–2087. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Russell NE, Higgins MF, Amaruso M, Foley M and McAuliffe FM: Troponin T and pro-B-type natriuretic Peptide in fetuses of type 1 diabetic mothers. Diabetes Care. 32:2050–2055. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Betti I, Castelli G, Barchielli A, Beligni C, Boscherini V, De Luca L, Messeri G, Gheorghiade M, Maisel A and Zuppiroli A: The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. J Card Fail. 15:377–384. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Chiu AP, Bierende D, Lal N, Wang F, Wan A, Vlodavsky I, Hussein B and Rodrigues B: Dual effects of hyperglycemia on endothelial cells and cardiomyocytes to enhance coronary LPL activity. Am J Physiol Heart Circ Physiol. 314:H82–h94. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Poornima IG, Parikh P and Shannon RP: Diabetic cardiomyopathy: The search for a unifying hypothesis. Circ Res. 98:596–605. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Du X, Matsumura T, Edelstein D, Rossetti L, Zsengellér Z, Szabó C and Brownlee M: Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest. 112:1049–1057. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Cai L, Li W, Wang G, Guo L, Jiang Y and Kang YJ: Hyperglycemia-induced apoptosis in mouse myocardium: Mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes. 51:1938–1948. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, et al: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 404:787–790. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Mavrogiannaki AN and Migdalis IN: Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: Newer data. Int J Endocrinol. 2013:4506392013. View Article : Google Scholar : PubMed/NCBI | |
|
Mracek T, Gao D, Tzanavari T, Bao Y, Xiao X, Stocker C, Trayhurn P and Bing C: Downregulation of zinc-{alpha}2-glycoprotein in adipose tissue and liver of obese ob/ob mice and by tumour necrosis factor-alpha in adipocytes. J Endocrinol. 204:165–172. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wende AR and Abel ED: Lipotoxicity in the heart. Biochim Biophys Acta. 1801:311–319. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
van de Weijer T, Schrauwen-Hinderling VB and Schrauwen P: Lipotoxicity in type 2 diabetic cardiomyopathy. Cardiovasc Res. 92:10–18. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Raeis V, Philip-Couderc P, Roatti A, Habre W, Sierra J, Kalangos A, Beghetti M and Baertschi AJ: Central venous hypoxemia is a determinant of human atrial ATP-sensitive potassium channel expression: Evidence for a novel hypoxia-inducible factor 1alpha-Forkhead box class O signaling pathway. Hypertension. 55:1186–1192. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ouwens DM, Diamant M, Fodor M, Habets DDJ, Pelsers MMAL, El Hasnaoui M, Dang ZC, van den Brom CE, Vlasblom R, Rietdijk A, et al: Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat diet is associated with elevated CD36-mediated fatty acid uptake and esterification. Diabetologia. 50:1938–1948. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ritchie RH, Love JE, Huynh K, Bernardo BC, Henstridge DC, Kiriazis H, Tham YK, Sapra G, Qin C, Cemerlang N, et al: Enhanced phosphoinositide 3-kinase(p110α) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes. Diabetologia. 55:3369–3381. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Durgan DJ, Moore MW, Ha NP, Egbejimi O, Fields A, Mbawuike U, Egbejimi A, Shaw CA, Bray MS, Nannegari V, et al: Circadian rhythms in myocardial metabolism and contractile function: Influence of workload and oleate. Am J Physiol Heart Circ Physiol. 293:H2385–H2393. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Harmancey R, Lam TN, Lubrano GM, Guthrie PH, Vela D and Taegtmeyer H: Insulin resistance improves metabolic and contractile efficiency in stressed rat heart. FASEB J. 26:3118–3126. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Feng B, Chen S, Chiu J, George B and Chakrabarti S: Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level. Am J Physiol Endocrinol Metab. 294:E1119–E1126. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yusuf J, Khan MU, Cheema Y, Bhattacharya SK and Weber KT: Disturbances in calcium metabolism and cardiomyocyte necrosis. Prog Cardiovasc Dis. 55:77–86. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Shamoo AE and Ambudkar IS: Regulation of calcium transport in cardiac cells. Can J Physiol Pharmacol. 62:9–22. 1984. View Article : Google Scholar : PubMed/NCBI | |
|
Barry WH and Bridge JH: Intracellular calcium homeostasis in cardiac myocytes. Circulation. 87:1806–1815. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Bigi MAB, Faramarzi H, Gaeini AA, Ravasi AA, Izadi MR, Delfan M and Izadi E: Upregulation of ryanodine receptor calcium channels (RyR2) in rats with induced diabetes after 4 weeks of high intensity interval training. Int Cardiovasc Res J. 10:1–5. 2016. View Article : Google Scholar | |
|
Uthman L, Baartscheer A, Schumacher CA, Fiolet JWT, Kuschma MC, Hollmann MW, Coronel R, Weber NC and Zuurbier CJ: Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients. Front Physiol. 9:15752018. View Article : Google Scholar : PubMed/NCBI | |
|
Ghazi L and Drawz P: Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy. F1000Res. 6(pii): F1000 Faculty Rev. –1297. 2017.PubMed/NCBI | |
|
Underwood PC and Adler GK: The renin angiotensin aldosterone system and insulin resistance in humans. Curr Hypertens Rep. 15:59–70. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Pacurari M, Kafoury R, Tchounwou PB and Ndebele K: The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflam. 2014:6893602014. View Article : Google Scholar : PubMed/NCBI | |
|
Lim HS, MacFadyen RJ and Lip GY: Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart. Arch Intern Med. 164:1737–1748. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Cooper ME: The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens. 17:16S–20S.A2-A4. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ohkura SI, Usui S, Takashima SI, Takuwa N, Yoshioka K, Okamoto Y, Inagaki Y, Sugimoto N, Kitano T, Takamura M, et al: Augmented sphingosine 1 phosphate receptor-1 signaling in cardiac fibroblasts induces cardiac hypertrophy and fibrosis through angiotensin II and interleukin-6. PLoS One. 12:e01823292017. View Article : Google Scholar : PubMed/NCBI | |
|
Bugger H and Abel ED: Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 57:660–671. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Al Hroob AM, Abukhalil MH, Hussein OE and Mahmoud AM: Pathophysiological mechanisms of diabetic cardiomyopathy and the therapeutic potential of epigallocatechin-3-gallate. Biomed Pharmacother. 109:2155–2172. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Marwick TH, Ritchie R, Shaw JE and Kaye D: Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol. 71:339–351. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Westermeier F, Riquelme JA, Pavez M, Garrido V, Díaz A, Verdejo HE, Castro PF, García L and Lavandero S: New molecular insights of insulin in diabetic cardiomyopathy. Front Physiol. 7:1252016. View Article : Google Scholar : PubMed/NCBI | |
|
Nakamura H, Matoba S, Iwai-Kanai E, Kimata M, Hoshino A, Nakaoka M, Katamura M, Okawa Y, Ariyoshi M, Mita Y, et al: p53 promotes cardiac dysfunction in diabetic mellitus caused by excessive mitochondrial respiration-mediated reactive oxygen species generation and lipid accumulation. Circ Heart Fail. 5:106–115. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Limas C and Limas CJ: Reduced number of beta-adrenergic receptors in the myocardium of spontaneously hypertensive rats. Biochem Biophys Res Commun. 83:710–714. 1978. View Article : Google Scholar : PubMed/NCBI | |
|
Lorenz K, Rosner MR, Brand T and Schmitt JP: Raf kinase inhibitor protein: Lessons of a better way for β-adrenergic receptor activation in the heart. J Physiol. 595:4073–4087. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wallukat G: The beta-adrenergic receptors. Herz. 27:683–690. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Q, Dalic A, Fang L, Kiriazis H, Ritchie RH, Sim K, Gao XM, Drummond G, Sarwar M, Zhang YY, et al: Myocardial oxidative stress contributes to transgenic β₂-adrenoceptor activation-induced cardiomyopathy and heart failure. Br J Pharmacol. 162:1012–1028. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Day RT, Cavaglieri Rde C, Tabatabaimir H, Mantravadi V, Lee MJ, Barnes JL, Kasinath BS and Feliers D: Acute hyperglycemia rapidly stimulates VEGF mRNA translation in the kidney. Role of angiotensin type 2 receptor (AT2). Cell Signal. 22:1849–1857. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ali MO: Pulmonary complications in diabetes mellitus. Mymensingh Med J. 23:603–605. 2014.PubMed/NCBI | |
|
Pavlov VI, La Bonte LR, Baldwin WM, Markiewski MM, Lambris JD and Stahl GL: Absence of mannose-binding lectin prevents hyperglycemic cardiovascular complications. Am J Pathol. 180:104–112. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Tang M, Zhou F, Zhang W, Guo Z, Shang Y, Lu H, Lu R, Zhang Y, Chen Y and Zhong M: The role of thrombospondin-1-mediated TGF-β1 on collagen type III synthesis induced by high glucose. Mol Cell Biochem. 346:49–56. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Guo Y, Zhuang X, Huang Z, Zou J, Yang D, Hu X, Du Z, Wang L and Liao X: Klotho protects the heart from hyperglycemia-induced injury by inactivating ROS and NF-κB-mediated inflammation both in vitro and in vivo. Biochim Biophys Acta Mol Basis Dis. 1864:238–251. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JM, Calkins MJ, Chan K, Kan YW and Johnson JA: Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem. 278:12029–12038. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Kwak MK, Itoh K, Yamamoto M and Kensler TW: Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: Role of antioxidant response element-like sequences in the nrf2 promoter. Mol Cell Biol. 22:2883–2892. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Mercado N, Thimmulappa R, Thomas CM, Fenwick PS, Chana KK, Donnelly LE, Biswal S, Ito K and Barnes PJ: Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem Biophys Res Commun. 406:292–298. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yoh K, Hirayama A, Ishizaki K, Yamada A, Takeuchi M, Yamagishi S, Morito N, Nakano T, Ojima M, Shimohata H, et al: Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells. 13:1159–1170. 2008.PubMed/NCBI | |
|
He X, Kan H, Cai L and Ma Q: Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes. J Mol Cell Cardiol. 46:47–58. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Cosso L, Maineri EP, Traverso N, Rosatto N, Pronzato MA, Cottalasso D, Marinari UM and Odetti P: Induction of heme oxygenase 1 in liver of spontaneously diabetic rats. Free Radic Res. 34:189–191. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Shi S, Lei S, Tang C, Wang K and Xia Z: Melatonin attenuates acute kidney ischemia/reperfusion injury in diabetic rats by activation of the SIRT1/Nrf2/HO-1 signaling pathway. Biosci Rep. 39(pii): BSR201816142019. View Article : Google Scholar : PubMed/NCBI | |
|
Ye Z, Guo Q, Xia P, Wang N, Wang E and Yuan Y: Sevoflurane postconditioning involves an up-regulation of HIF-1α and HO-1 expression via PI3K/Akt pathway in a rat model of focal cerebral ischemia. Brain Res. 1463:63–74. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Tsuchihashi S, Fondevila C and Kupiec-Weglinski JW: Heme oxygenase system in ischemia and reperfusion injury. Ann Transplant. 9:84–87. 2004.PubMed/NCBI | |
|
Mallick IH, Winslet MC and Seifalian AM: Pyrrolidine dithiocarbamate protects the small bowel from warm ischaemia/reperfusion injury of the intestine: The role of haem oxygenase. Clin Sci (Lond). 111:373–380. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Chen YH, Yet SF and Perrella MA: Role of heme oxygenase-1 in the regulation of blood pressure and cardiac function. Exp Biol Med (Maywood). 228:447–453. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Bai CH, Chen JR, Chiu HC, Chou CC, Chau LY and Pan WH: Shorter GT repeat polymorphism in the heme oxygenase-1 gene promoter has protective effect on ischemic stroke in dyslipidemia patients. J Biomed Sci. 17:122010. View Article : Google Scholar : PubMed/NCBI | |
|
Nieto MA, Huang RY, Jackson RA and Thiery JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kong P, Christia P and Frangogiannis NG: The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 71:549–574. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
García R, Nistal JF, Merino D, Price NL, Fernández-Hernando C, Beaumont J, González A, Hurlé MA and Villar AV: p-SMAD2/3 and DICER promote pre-miR-21 processing during pressure overload-associated myocardial remodeling. Biochim Biophys Acta. 1852:1520–1530. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Niu L, Cui X, Qi Y, Xie D, Wu Q, Chen X, Ge J and Liu Z: Involvement of TGF-β1/Smad3 signaling in carbon tetrachloride-induced acute liver injury in mice. PLoS One. 11:e01560902016. View Article : Google Scholar : PubMed/NCBI | |
|
Li TT, Si GM and Chen FC: Effects of Shenqi Jiedu Decoction on expressions of transforming growth factor-beta1, smad2 and smad3 in renal tissues of rats with chronic renal failure induced by adenine. Zhong Xi Yi Jie He Xue Bao. 8:263–268. 2010.(In Chinese). View Article : Google Scholar : PubMed/NCBI | |
|
Nelson EF, Huang CW, Ewel JM, Chang AA and Yuan C: Halofuginone down-regulates Smad3 expression and inhibits the TGFbeta-induced expression of fibrotic markers in human corneal fibroblasts. Mol Vis. 18:479–487. 2012.PubMed/NCBI | |
|
Dong C, Mi R, Jin G, Zhou Y, Zhang J and Liu F: Identification of the proliferative effect of Smad2 and 3 in the TGF β2/Smad signaling pathway using RNA interference in a glioma cell line. Mol Med Rep. 12:1824–1828. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Piek E, Wen JJ, Heyer J, Escalante-Alcalde D, Stewart CL, Weinstein M, Deng C, Kucherlapati R, Bottinger EP and Roberts AB: Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts. J Biol Chem. 276:19945–19953. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Feng XH, Liang YY, Liang M, Zhai W and Lin X: Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B). Mol Cell. 9:133–143. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Li P, Oparil S, Novak L, Cao X, Shi W, Lucas J and Chen YF: ANP signaling inhibits TGF-beta-induced Smad2 and Smad3 nuclear translocation and extracellular matrix expression in rat pulmonary arterial smooth muscle cells. J Appl Physiol (1985). 102:390–398. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Divakaran V, Adrogue J, Ishiyama M, Entman ML, Haudek S, Sivasubramanian N and Mann DL: Adaptive and maladptive effects of SMAD3 signaling in the adult heart after hemodynamic pressure overloading. Circ Heart Fail. 2:633–642. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Van der Heiden K, Cuhlmann S, Luong le A, Zakkar M and Evans PC: Role of nuclear factor kappaB in cardiovascular health and disease. Clin Sci (Lond). 118:593–605. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hink U, Tsilimingas N, Wendt M and Munzel T: Mechanisms underlying endothelial dysfunction in diabetes mellitus: Therapeutic implications. Treat Endocrinol. 2:293–304. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Sugiyama S, Miyata T, Ueda Y, Tanaka H, Maeda K, Kawashima S, Van Ypersele de Strihou C and Kurokawa K: Plasma levels of pentosidine in diabetic patients: An advanced glycation end product. J Am Soc Nephrol. 9:1681–1688. 1998.PubMed/NCBI | |
|
Kanauchi M, Tsujimoto N and Hashimoto T: Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care. 24:1620–1623. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Hussain F, Sheikh MA, Maan MA and Jamil A: Advanced glycation end products (AGEs) in diabetic patients with systemic lupus erythematosus. Int J Agric Biol. 14:440–444. 2012. | |
|
Choi EY, Kwon HM, Ahn CW, Lee GT, Joung B, Hong BK, Yoon YW, Kim D, Byun KH, Kang TS, et al: Serum levels of advanced glycation end products are associated with in-stent restenosis in diabetic patients. Yonsei Med J. 46:78–85. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Khalifah RG, Todd P, Booth AA, Yang SX, Mott JD and Hudson BG: Kinetics of nonenzymatic glycation of ribonuclease A leading to advanced glycation end products. Paradoxical inhibition by ribose leads to facile isolation of protein intermediate for rapid post-Amadori studies. Biochemistry. 35:4645–4654. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Vlassara H: Advanced glycation end-products and atherosclerosis. Ann Med. 28:419–426. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Peppa M and Vlassara H: Advanced glycation end products and diabetic complications: A general overview. Hormones (Athens). 4:28–37. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Nożyński J, Zakliczyński M, Konecka-Mrowka D, Zielinska T, Zakliczynska H, Nikiel B, Mlynarczyk-Liszka J, Mrowka A, Zembala-Nozynska E, Pijet M, et al: Advanced glycation end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes. Ann Transplant. 17:53–61. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Grzebyk E, Knapik-Kordecka M and Piwowar A: Advanced glycation end-products and cathepsin cysteine protease in type 2 diabetic patients. Pol Arch Med Wewn. 123:364–370. 2013.PubMed/NCBI | |
|
Kuwajima S: Immunochemical determination of advanced glycation end products in erythrocyte peripheral-membrane proteins from diabetic patients. Hokkaido Igaku Zasshi. 68:695–704. 1993.(In Japanese). PubMed/NCBI | |
|
Low H, Hoang A, Forbes J, Thomas M, Lyons JG, Nestel P, Bach LA and Sviridov D: Advanced glycation end-products (AGEs) and functionality of reverse cholesterol transport in patients with type 2 diabetes and in mouse models. Diabetologia. 55:2513–2521. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Singh VP, Bali A, Singh N and Jaggi AS: Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 18:1–14. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Feng Y, Zhao H, Xu X, Buys ES, Raher MJ, Bopassa JC, Thibault H, Scherrer-Crosbie M, Schmidt U and Chao W: Innate immune adaptor MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. Am J Physiol Heart Circ Physiol. 295:H1311–H1318. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Weber NC, Toma O, Wolter JI, Obal D, Müllenheim J, Preckel B and Schlack W: The noble gas xenon induces pharmacological preconditioning in the rat heart in vivo via induction of PKC-epsilon and p38 MAPK. Br J Pharmacol. 144:123–132. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Das Evcimen N and King GL: The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res. 55:498–510. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Koya D and King GL: Protein kinase C activation and the development of diabetic complications. Diabetes. 47:859–866. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Nogueira-Machado JA and Bosco AA: PKC inhibition and diabetic complications. Recent Patents End Metab Immune Drug Discov. 2:72–78. 2008. View Article : Google Scholar | |
|
Ishii H, Koya D and King GL: Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med (Berl). 76:21–31. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Shen GX: Selective protein kinase C inhibitors and their applications. Curr Drug Targets Cardiovasc Haematol Disord. 3:301–307. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Bursell SE and King GL: Can protein kinase C inhibition and vitamin E prevent the development of diabetic vascular complications? Diabetes Res Clin Pract. 45:169–182. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Jia G, DeMarco VG and Sowers JR: Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 12:144–153. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lee TI, Kao YH, Chen YC, Huang JH, Hsiao FC and Chen YJ: Peroxisome proliferator-activated receptors modulate cardiac dysfunction in diabetic cardiomyopathy. Diabetes Res Clin Pract. 100:330–339. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD and Kelly DP: The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 109:121–130. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Leone TC, Weinheimer CJ and Kelly DP: A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: The PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA. 96:7473–7478. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Pedraza N, Rosell M, Villarroya J, Iglesias R, Gonzalez FJ, Solanes G and Villarroya F: Developmental and tissue-specific involvement of peroxisome proliferator-activated receptor-alpha in the control of mouse uncoupling protein-3 gene expression. Endocrinology. 147:4695–4704. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L and Unger RH: Lipotoxic heart disease in obese rats: Implications for human obesity. Proc Natl Acad Sci USA. 97:1784–1789. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Anderson EJ, Kypson AP, Rodriguez E, Anderson CA, Lehr EJ and Neufer PD: Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol. 54:1891–1898. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Razeghi P, Young ME, Cockrill TC, Frazier OH and Taegtmeyer H: Downregulation of myocardial myocyte enhancer factor 2C and myocyte enhancer factor 2C-regulated gene expression in diabetic patients with nonischemic heart failure. Circulation. 106:407–411. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N, Evans RM, Schneider MD, Brako FA, Xiao Y, et al: Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med. 10:1245–1250. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Scirpo R, Fiorotto R, Villani A, Fabris L and Strazzabosco M: Stimulation of Nuclear Receptor PPAR-γ Limits NF-kB-dependent inflammation in cystic fibrosis biliary epithelium. Dig Liver Dis. 47:e43–e44. 2015. View Article : Google Scholar | |
|
Ng DC, Long CS and Bogoyevitch MA: A role for the extracellular signal-regulated kinase and p38 mitogen-activated protein kinases in Interleukin-1beta-stimulated delayed signal tranducer and activator of transcription3 activation, atrial natriuretic factor expression and cardiac myocyte morphology. J Biol Chem. 276:29490–29498. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Lei Y, Xu Q, Zeng B, Zhang W, Zhen Y, Zhai Y, Cheng F, Mei W, Zheng D, Feng J, et al: Angiotensin-(1–7) protects cardiomyocytes against high glucose-induced injuries through inhibiting reactive oxygen species-activated leptin-p38 mitogen-activated protein kinase/extracellular signal-regulated protein kinase 1/2 pathways but not leptin-c-Jun N-terminal kinase pathway in vitro. J Diabetes Investig. 8:434–445. 2016. View Article : Google Scholar | |
|
Bo B, Tang J, Liu H, Chen J, Li Y and Song W: Apelin-13 induces ERK1/2 but not p38 MAPK activation through coupling of the human apelin receptor to the Gi2 pathway. Acta Biochim Biophys Sin (Shanghai). 40:311–318. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kiribayashi K, Masaki T, Naito T, Ogawa T, Ito T, Yorioka N and Kohno N: Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK. Kidney Int. 67:1126–1135. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Blanc A, Pandey NR and Srivastava AK: Synchronous activation of ERK 1/2, p38mapk and PKB/Akt signaling by H2O2 in vascular smooth muscle cells: Potential involvement in vascular disease (review). Int J Mol Med. 11:229–234. 2003.PubMed/NCBI | |
|
Strniskova M, Barancik M, Neckar J and Ravingerova T: Mitogen-activated protein kinases in the acute diabetic myocardium. Mol Cell Biochem. 249:59–65. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Jia G, Habibi J, DeMarco VG, Martinez-Lemus LA, Ma L, Whaley-Connell AT, Aroor AR, Domeier TL, Zhu Y, Meininger GA, et al: Endothelial mineralocorticoid receptor deletion prevents diet-induced cardiac diastolic dysfunction in females. Hypertension. 66:1159–1167. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Rouf R, MacFarlane EG, Takimoto E, Chaudhary R, Nagpal V, Rainer PP, Bindman JG, Gerber EE, Bedja D, Schiefer C, et al: Nonmyocyte ERK1/2 signaling contributes to load-induced cardiomyopathy in Marfan mice. JCI Insight. 2(pii): 915882017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Zhou S, Sun W, McClung K, Pan Y, Liang G, Tan Y, Zhao Y, Liu Q, Sun J and Cai L: Inhibition of JNK by novel curcumin analog C66 prevents diabetic cardiomyopathy with a preservation of cardiac metallothionein expression. Am J Physiol Endocrinol Metab. 306:E1239–E1247. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Gurusamy N, Watanabe K, Ma M, Zhang S, Muslin AJ, Kodama M and Aizawa Y: Dominant negative 14-3-3 promotes cardiomyocyte apoptosis in early stage of type I diabetes mellitus through activation of JNK. Biochem Biophys Res Commun. 320:773–780. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Hardie DG: AMP-activated/SNF1 protein kinases: Conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 8:774–785. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Herzig S and Shaw RJ: AMPK: Guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 19:121–135. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Shaw RJ: LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf). 196:65–80. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Xu K, Liu XF, Ke ZQ, Yao Q, Guo S and Liu C: Resveratrol modulates apoptosis and autophagy induced by high glucose and palmitate in cardiac cells. Cell Physiol Biochem. 46:2031–2040. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Jweied EE, Mckinney RD, Walker LA, Brodsky I, Geha AS, Massad MG, Buttrick PM and de Tombe PP: Depressed cardiac myofilament function in human diabetes mellitus. Am J Physiol Heart Circ Physiol. 289:H2478–H2483. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Khullar M, Cheema BS and Raut SK: Emerging evidence of epigenetic modifications in vascular complication of diabetes. Front Endocrinol (Lausanne). 8:2372017. View Article : Google Scholar : PubMed/NCBI | |
|
Barwari T, Joshi A and Mayr M: MicroRNAs in cardiovascular disease. J Am Coll Cardiol. 68:2577–2584. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, et al: Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 107:810–817. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Q, Qiu F, Zhou K, Matlock HG, Takahashi Y, Rajala RVS, Yang Y, Moran E and Ma JX: Pathogenic Role of microRNA-21 in Diabetic Retinopathy Through Downregulation of PPARα. Diabetes. 66:1671–1682. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Rawal S, Munasinghe PE, Nagesh PT, Lew JKS, Jones GT, Williams MJA, Davis P, Bunton D, Galvin IF, Manning P, et al: Down-regulation of miR-15a/b accelerates fibrotic remodelling in the Type 2 diabetic human and mouse heart. Clin Sci (Lond). 131:847–863. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Assmann TS, Recamonde-Mendoza M, De Souza BM and Crispim D: MicroRNA expression profiles and type 1 diabetes mellitus: Systematic review and bioinformatic analysis. Endocr Connect. 6:773–790. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Demirsoy IH, Ertural DY, Balci S, Çınkır Ü, Sezer K, Tamer L and Aras N: Profiles of circulating MiRNAs following metformin treatment in patients with type 2 diabetes. J Med Biochem. 37:499–506. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Prabu P, Rome S, Sathishkumar C, Gastebois C, Meugnier E, Mohan V and Balasubramanyam M: MicroRNAs from urinary extracellular vesicles are non-invasive early biomarkers of diabetic nephropathy in type 2 diabetes patients with the ‘Asian Indian phenotype’. Diabetes Metab. 45:276–285. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan M, Heim MH and Stoffel M: MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 474:649–653. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Nair N, Kumar S, Gongora E and Gupta S: Circulating miRNA as novel markers for diastolic dysfunction. Mol Cell Biochem. 376:33–40. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X and Liu S: Role of microRNAs in the pathogenesis of diabetic cardiomyopathy. Biomed Rep. 6:140–145. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lee WS and Kim J: Diabetic cardiomyopathy: Where we are and where we are going. Korean J Intern Med. 32:404–421. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J and Baigent C: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet. 371:117–125. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cosmi F and Cosmi D: Hypoglycemic therapy in heart disease patients with type 2 diabetes mellitus. G Ital Cardiol (Rome). 11:460–466. 2010.(In Italian). PubMed/NCBI | |
|
Anabtawi A, Moriarty PM and Miles JM: Pharmacologic treatment of dyslipidemia in diabetes: A case for therapies in addition to statins. Curr Cardiol Rep. 19:622017. View Article : Google Scholar : PubMed/NCBI | |
|
Brea A, Millán J, Ascaso JF, Blasco M, Díaz A, Hernández-Mijares A, Mantilla T, Pedro-Botet JC and Pintó X: Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration. Clin Investig Arterioscler. 30:188–192. 2018.(In English, Spanish). PubMed/NCBI | |
|
Thomas CM, Yong QC, Seqqat R, Chandel N, Feldman DL, Baker KM and Kumar R: Direct renin inhibition prevents cardiac dysfunction in a diabetic mouse model: Comparison with an angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor. Clin Sci (Lond). 124:529–541. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Machackova J, Liu X, Lukas A and Dhalla NS: Renin-angiotensin blockade attenuates cardiac myofibrillar remodelling in chronic diabetes. Mol Cell Biochem. 261:271–278. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Bangalore S, Messerli FH, Kostis JB and Pepine CJ: Cardiovascular protection using beta-blockers: A critical review of the evidence. J Am Coll Cardiol. 50:563–572. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma V and McNeill JH: Parallel effects of β-adrenoceptor blockade on cardiac function and fatty acid oxidation in the diabetic heart: Confronting the maze. World J Cardiol. 3:281–302. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mohamad HE, Askar ME and Hafez MM: Management of cardiac fibrosis in diabetic rats; the role of peroxisome proliferator activated receptor gamma (PPAR-gamma) and calcium channel blockers (CCBs). Diabetol Metab Syndr. 3:42011. View Article : Google Scholar : PubMed/NCBI | |
|
Ellestad MH: Hyperbaric oxygen: Its application in cardiology: A historical perspective and personal journey. Cardiol Rev. 17:280–282. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Karadurmus N, Sahin M, Tasci C, Naharci I, Ozturk C, Ilbasmis S, Dulkadir Z, Sen A and Saglam K: Potential benefits of hyperbaric oxygen therapy on atherosclerosis and glycaemic control in patients with diabetic foot. Endokrynol Pol. 61:275–279. 2010.PubMed/NCBI | |
|
Katare R, Caporali A, Zentilin L, Avolio E, Sala-Newby G, Oikawa A, Cesselli D, Beltrami AP, Giacca M, Emanueli C and Madeddu P: Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling. Circ Res. 108:1238–1251. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng Y, Guo S, Liu G, Feng Y, Yan B, Yu J, Feng K and Li Z: Transplantation of bone marrow-derived endothelial progenitor cells attenuates myocardial interstitial fibrosis and cardiac dysfunction in streptozotocin-induced diabetic rats. Int J Mol Med. 30:870–876. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Neel S and Singla DK: Induced pluripotent stem (iPS) cells inhibit apoptosis and fibrosis in streptozotocin-induced diabetic rats. Mol Pharm. 8:2350–2357. 2011. View Article : Google Scholar : PubMed/NCBI |
